• Local Time
  • Last Revised
    08.03.2010
  • Company
  • Pipeline
  • Partnerships
  • Investors
  • Events
  • News
  • Careers
  • Contact Us
Home

Site Map

  • Print page
  • Email this page
  • Download Acrobat Reader PDF
  • Company
    • About Us
    • Strategy
    • Senior Management
    • Advisory Board
  • Pipeline
    • Dersalazine sodium
    • UR-13870 (p38 MAPK inhibitor)
    • UR-63325 (H4R antagonist)
    • UR-65318 (H4R antagonist)
    • UR-67767 (Jak inhibitor)
    • Neogenius Pharma
    • Technology
    • Special Consortiums
  • Partnerships
    • Our Partners
    • Partnering with us
  • Investors
  • Events
  • News
  • Careers
  • Contact Us
  • Terms of use
  • Privacy Policy

Direct Access

  • About Us
  • Strategy
  • Senior Management
  • Advisory Board
  • Dersalazine sodium
  • UR-13870 (p38 MAPK inhibitor)
  • UR-63325 (H4R antagonist)
  • UR-65318 (H4R antagonist)
  • UR-67767 (Jak inhibitor)
  • Neogenius Pharma
  • Technology
  • Special Consortiums
  • Our partners
  • Partnering with us
  • Investors
  • Events
  • Site Map
  • Terms of use
  • Privacy Policy
  • Contact Us
  • © Palau Pharma 2010
Developed by Xtranet